Mercy Health announces that the Blood Cancer Center at The Jewish Hospital is celebrating its 30th anniversary this year.

The Blood Cancer Center has performed over 2,200 bone marrow transplants since it opened in 1989, saving and extending the lives of many patients, and it continues to innovate.

This year, working together with its cancer experts from OHC, the Blood Cancer Center became the first adult treatment center in Cincinnati to offer Chimeric Antigen Receptor (CAR) T-Cell Therapy, also known as CAR-T, for patients with certain blood cancers. This is a leading-edge treatment for adults with aggressive blood cancers that has helped many patients previously considered terminal to go into remission with good quality of life, demonstrated for up to five years.

“The Blood Cancer Center started as the most advanced adult blood and bone marrow transplant program in the Tristate and it has retained its leadership position over 30 years,” said Pat Davis-Hagens, President of The Jewish Hospital – Mercy Health. “When patients and their loved ones enter our doors, they become family. It’s that deep bond that inspires the Blood Cancer Center’s care team to provide the heartfelt, quality care that has impacted the lives of so many across the region.”

Mercy Health partners with OHC, the largest group of independent medical, gynecologic and radiation oncologists and hematologists in the Tristate, to provide care at the Blood Cancer Center. 

“As a physician, I have always wanted to offer a sense of hope to our patients. I’m grateful to have that opportunity every day thanks to the team at the Blood Cancer Center and to my research colleagues at OHC who joined me in bringing CAR-T therapy and other innovative treatments to the region,” said James H. Essell, MD, OHC medical oncologist, hematologist and medical director of the Blood Cancer Center.

Nationally recognized and accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), the Blood Cancer Center has earned the Gold Seal of Approval® from the Joint Commission—a disease-specific care certification. Its overall patient survival rates are comparable to those of MD Anderson and the Cleveland Clinic.

The state-of-the-art transplant facility includes 28 private rooms, six of which are ICU rooms designated for blood cancer patients requiring critical care. An acute rehabilitation unit, outpatient clinic and infusion center are also located on the same floor as the inpatient unit providing ease of access for both patients and caregivers. 

Each year, the team treats more than 120 new patients with acute leukemia and high-grade lymphoma with procedures including autologous, allogeneic, syngeneic (from an identical twin) and haplo-identical (half matched donor) transplants. The Jewish Hospital Blood Cancer Center participates in a wide range of research studies, giving patients access to leading-edge treatments and clinical trials as soon as they are available.